Compositions and methods for antibodies targeting factor p

An isolated antibody, or antigen binding fragment, that binds Factor P, said antibody or antigen binding fragment comprising:

• a) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 1, 2, and 3, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 4, 5, and 6, respectively;
• b) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 15, 16, and 17, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 18, 19, and 20, respectively;
• c) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 29, 30, and 31, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 32, 33, and 34, respectively;
• d) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 43, 44, and 45, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 46, 47, and 48, respectively;
• e) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 57, 58, and 59, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 60, 61, and 62, respectively;
• f) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 71, 72, and 73, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 74, 75, and 76, respectively;
• g) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 85, 86, and 87, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 88, 89, and 90, respectively;
• h) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 99, 100, and 101, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 102, 103, and 104, respectively;
• i) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 113, 114, and 115, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 116, 117, and 118, respectively;
• j) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 127, 128, and 129, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 130, 131, and 132, respectively;
• k) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 141, 142, and 143, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 144, 145, and 146, respectively;
• l) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 155, 156, and 157, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 158, 159, and 160, respectively;
• m) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 169, 170, and 171, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 172, 173, and 174, respectively;
• n) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 183, 184, and 185, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 186, 187, and 188, respectively;
• o) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 197, 198, and 199, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 200, 201, and 202, respectively;
• p) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 211, 212, and 213, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 214, 215, and 216, respectively;
• q) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 225, 226, and 227, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 228, 229, and 230, respectively;
• r) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 239, 240, and 241, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 242, 243, and 244, respectively;
• s) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 253, 254, and 255, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 256, 257, and 258, respectively;
• or
• t) heavy chain variable region HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NOs:
• 267, 268, and 269, respectively, and light chain variable region LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NOs:
• 270, 271, and 272, respectively.

The antibody, or antigen binding fragment, of any preceding claim comprising heavy and light chain variable regions having amino acid sequences at least 90% identical to SEQ ID NOs:

• 7 and 8;
• SEQ ID NOs:
• 21 and 22;
• SEQ ID NOs:
• 35 and 36;
• SEQ ID NOs:
• 49 and 50;
• SEQ ID NOs:
• 63 and 64;
• SEQ ID NOs:
• 77 and 78;
• SEQ ID NOs:
• 91 and 92;
• SEQ ID NOs:
• 105 and 106;
• SEQ ID NOs:
• 119 and 120;
• SEQ ID NOs:
• 133 and 134;
• SEQ ID NOs:
• 147 and 148;
• SEQ ID NOs:
• 161 and 162;
• SEQ ID NOs:
• 175 and 176;
• SEQ ID NOs:
• 189 and 190;
• SEQ ID NOs:
• 203 and 204;
• SEQ ID NOs:
• 217 and 218;
• SEQ ID NOs:
• 231 and 232;
• SEQ ID NOs:
• 245 and 246;
• SEQ ID NOs:
• 259 and 260;
• or SEQ ID NOs:
• 273 and 274, respectively.